A recent meta-analysis concludes that a postoperative combination of radiotherapy, chemotherapy and PD-1 inhibitors may increase antigen cross-presentation activity, promote tumor-lymphocyte infiltration, and increase the expansion of effector T cells. The gene discussed is PDCD1; the disease is neoplasm.